AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

AtomVie-ClinicalStudy

More Like This

PR Newswire associated0

AtomVie Global Radiopharma and Radiopharm Theranostics Partner to Develop and Manufacture 177Lu-BetaBart Radioantibody for Treatment of Multiple Solid Tumors

PR Newswire associated0

AtomVie Global Radiopharma Supplies the First Patient Dose of 225Ac-SSO110 for Ariceum Therapeutics' Phase 1/2 SANTANA-225 Clinical Trial in Extensive-Stage Small Cell Lung Cancer and Merkel Cell Carcinoma

PR Newswire associated0

AtomVie Global Radiopharma Secures a Supply Agreement with Ionetix Corporation to Accelerate Ac-225 Radiotherapeutics Development

PR Newswire associated0

Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply

PR Newswire associated0

AtomVie Global Radiopharma and TerraPower Isotopes Announce Strategic Supply Agreement for Actinium-225 to Advance Radiopharmaceutical Development and Manufacturing

PR Newswire associated0

AtomVie Global Radiopharma Collaborates with RLS & UPPI to Strengthen its Existing U.S. Radiotherapeutic Distribution Network

PR Newswire associated0

First Patients in the UK Receive Doses of Blue Earth Therapeutics' Investigational Radiopharmaceutical Therapy Lutetium (177Lu) rhPSMA-10.1 Injection for Metastatic Castrate Resistant Prostate Cancer

PR Newswire associated0

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors